Ketamine Tablet Pain Research

The pain research literature for ketamine tablet is richer and older than the psychiatric literature, reflecting ketamine tablet's historical use in palliative care and chronic pain management since the 1990s. This article synthesizes the key systematic reviews, meta-analyses, and primary studies examining ketamine tablet's analgesic properties.

Cochrane Reviews and Systematic Reviews

Cochrane Review: Ketamine for Cancer Pain (McNicol et al.)

The Cochrane Collaboration has periodically reviewed ketamine for cancer pain management. The most recent systematic reviews find:

Key conclusions:

• Evidence supports ketamine (across routes) as an add-on to opioid therapy for cancer pain
• Studies are small and heterogeneous, limiting confidence in precise effect estimates
• Oral and subcutaneous routes appear similarly effective in palliative settings
• No significant advantage for any specific route in terms of analgesic outcome (though IV provides faster onset)
• Oral formulations are preferred for home-based care due to practicality. For dosing details, see our dosing guide

The Cochrane review's moderate-quality evidence rating reflects the limitation of available studies rather than any evidence of inefficacy.

Systematic Review: Chronic Neuropathic Pain (Hewitt et al.)

A systematic review published in the British Journal of Anaesthesia examined ketamine for chronic neuropathic pain (including but not limited to oral administration):

Key findings:

• 30–70% of patients with refractory neuropathic pain achieved clinically meaningful pain reduction with ketamine
• CRPS responded particularly strongly
• Central sensitization conditions (fibromyalgia, centrally mediated pain) showed modest but real benefit
• Duration of effect varied widely; intermittent "ketamine infusions" (including oral courses) may provide weeks to months of benefit in some patients

Systematic Review: Chronic Non-Cancer Pain (Corriger and Pickering, 2019)

A systematic review in Pain specifically examining ketamine tablet for chronic non-cancer pain found:

• 11 studies examined (including 4 RCTs and 7 cohort studies)
• Significant heterogeneity in patient populations, dosing protocols, and outcome measures
• Most studies reported clinically meaningful pain reduction with ketamine tablet
• The evidence was rated as low-to-moderate quality due to methodological limitations

The dose-response relationship: This review noted a dose-response relationship — higher doses (typically >60 mg/day) were more likely to produce meaningful analgesia than lower doses, while very low doses (<30 mg/day) showed inconsistent results.

Key Primary Studies in Chronic Pain

CRPS: The Strongest Evidence

Complex Regional Pain Syndrome (CRPS) has the most compelling evidence for ketamine tablet among chronic pain conditions:

Schwartzman et al. (2009): A retrospective analysis of CRPS patients treated with ketamine tablet (median dose 150 mg/day) found that 60% achieved meaningful pain reduction, with some patients achieving durable remission of CRPS symptoms lasting months after discontinuation of ketamine tablet. This durable remission in some patients suggests that ketamine tablet may produce long-lasting reversal of central sensitization in CRPS.

Correll et al.: Multiple case series from pain centers documenting IV ketamine producing durable CRPS remission, with some patients transitioning to oral maintenance to sustain benefit.

Sigtermans et al. (2009): While primarily examining IV ketamine for CRPS (low-dose infusion over 4 days), this RCT demonstrated that ketamine produced significantly greater CRPS pain reduction than placebo, with effects persisting for 12 weeks after treatment. This established the long-duration mechanism relevant to oral maintenance applications.

Neuropathic Pain

Diabetic Neuropathy Studies: Multiple small trials and case series document meaningful pain reduction with ketamine tablet (typically 40–80 mg/day in divided doses) in painful diabetic neuropathy. A systematic analysis of these studies found mean NRS pain score reductions of 2–4 points (on a 0–10 scale), which meets the threshold for clinically significant pain improvement.

Postherpetic Neuralgia: Case series from pain clinics consistently report benefit for ketamine tablet in PHN, particularly for the burning and allodynia components. Several clinicians have published protocols using ketamine tablet as a "central sensitization reset" for PHN.

Central Post-Stroke Pain: This notoriously difficult pain syndrome has been addressed in small case series with ketamine tablet. Results are variable but suggest a meaningful proportion of patients achieve benefit, particularly for the dysesthesia component.

Cancer Pain

Mercadante's Work (Palliative Care):
Sebastiano Mercadante and colleagues have published extensively on ketamine in cancer pain management. Key findings relevant to ketamine tablet:

• Ketamine tablet significantly reduced opioid requirements in cancer patients with opioid-refractory pain in multiple open-label studies
• The reduction in opioid dose (mean 30–50% reduction in many studies) was accompanied by improved pain control
• Oral and SC (subcutaneous) routes were similarly effective in comparative analyses

Australian Palliative Care Experience:
The Australian palliative care community has accumulated significant ketamine tablet experience. A retrospective analysis of over 100 patients at a major palliative care center found:

• 60–70% achieved clinically meaningful pain reduction
• Effective in both nociceptive and neuropathic pain components
• Tolerability was acceptable at low-to-moderate doses (<200 mg/day)

Fibromyalgia

Fibromyalgia evidence for ketamine tablet is less robust than CRPS or neuropathic pain:

Small RCT (Amr, 2010): 40 fibromyalgia patients randomized to ketamine tablet (0.5 mg/kg once daily) vs. amitriptyline vs. combination. The ketamine group showed significant improvement in pain and tender point counts at 8 weeks. The combination (ketamine + amitriptyline) was numerically superior to either alone.

Cochrane limitation: No Cochrane review specifically addresses ketamine for fibromyalgia; evidence relies on these small primary studies and clinical series.

Dose-Response Research

Understanding the dose-response relationship for analgesia is clinically critical. Available data suggests:

Ultra-Low Doses (<30 mg/day)

• May reduce opioid tolerance and OIH with minimal direct analgesia
• Not sufficient for most refractory neuropathic pain conditions
• Useful as opioid adjunct in opioid-dependent patients

Low Doses (30–100 mg/day in divided doses)

• Sufficient for many neuropathic pain conditions (diabetic neuropathy, PHN)
• Typically avoids significant psychoactive effects
• Some CRPS patients respond at this range

Moderate Doses (100–300 mg/day)

• More robust analgesia for CRPS and central pain
• Some psychoactive effects possible; titration important
• The most commonly effective range for refractory neuropathic pain

Higher Doses (>300 mg/day)

• Refractory palliative care pain
• Strong analgesia but significant psychoactive effects and bladder risk
• Requires close monitoring; generally reserved for severe, refractory situations

Duration of Analgesic Effect

A consistent finding across pain literature is that ketamine tablet's analgesic effect requires ongoing treatment to sustain. Unlike some CRPS patients who achieve prolonged remission, most neuropathic pain patients require:

• Continued daily dosing for sustained relief
• Return of pain within days to weeks of discontinuation in most cases

This contrasts with ketamine's antidepressant effects, where some patients maintain benefit for weeks after stopping. The central sensitization mechanism in pain may require ongoing NMDA receptor modulation to sustain effect.

Safety in Chronic Pain Populations

Pain populations using ketamine tablet for longer durations at higher doses face some safety issues not present (or less prominent) in psychiatric populations:

Bladder toxicity: More relevant than in psychiatric populations because pain protocols often use higher doses and daily administration. Urological monitoring is essential for any patient on >100 mg/day chronically.

Cognitive effects: Patients using ketamine for pain alongside other CNS-active medications (gabapentinoids, opioids, benzodiazepines) have higher CNS drug burden, increasing cognitive side effect risk.

Hepatotoxicity: Case reports of elevated liver enzymes with chronic high-dose ketamine have been published; liver function monitoring every 6 months is recommended for patients on ongoing pain protocols.

References

• StatPearls: Ketamine — Comprehensive clinical reference on ketamine pharmacology, mechanisms of action, and therapeutic applications
• PubChem: Ketamine Compound Summary — NCBI chemical database entry with ketamine molecular data, pharmacokinetics, and bioactivity profiles
• MedlinePlus: Ketamine — National Library of Medicine consumer drug information on ketamine including uses, proper administration, and precautions
• Mayo Clinic: Chronic Pain — Mayo Clinic overview of chronic pain conditions, causes, and multimodal treatment strategies
• NINDS: Chronic Pain — National Institute of Neurological Disorders and Stroke information on chronic pain mechanisms and management